GlassScriptPhysician profile
Kara Roche
NPI 1811433923
$9,882.42
in general payments reported to CMS, 2019-2025
30 companies · $2,469 in 2025
The $2,469 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $858 · 2022: $1,578 · 2023: $1,662 · 2024: $3,315 · 2025: $2,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,216 · Consulting Fee: $1,063 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,215.50 |
| Consulting Fee | $1,062.50 |
| Education | $167.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,800.36 | 2021-2025 | Tremfya, Stelara, Remicade |
| Abbvie INC. | $2,145.43 | 2021-2025 | |
| Galderma Laboratories, L.P. | $619.72 | 2021-2025 | Nemluvio, Dysport, Aklief |
| Genzyme Corporation | $568.61 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $556.42 | 2021-2025 | |
| Dermavant Sciences, INC. | $362.06 | 2023-2024 | Vtama |
| Almirall LLC | $294.74 | 2022-2024 | Seysara, Klisyri |
| Lilly USA, LLC | $292.05 | 2021-2025 | Ebglyss, Taltz |
| Incyte Corporation | $240.05 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $225.45 | 2022-2025 | Absorica Ld, Winlevi, Ilumya |
| Ucb, INC. | $224.98 | 2024-2025 | Bimzelx |
| Pfizer INC. | $181.50 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $147.08 | 2022-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $140.51 | 2023-2025 | Zoryve |
| Journey Medical Corporation | $133.83 | 2023-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $133.55 | 2023-2025 | Hadlima, Nexplanon, Vtama |
| E.R. Squibb & Sons, L.L.C. | $97.02 | 2024-2025 | Sotyktu |
| Janssen Scientific Affairs, LLC | $93.99 | 2022 | |
| Leo Pharma INC. | $89.83 | 2022-2023 | Adbry |
| Sanofi-Aventis U.S. LLC | $85.00 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.36 | 2023-2024 | Spevigo |
| Verrica Pharmaceuticals INC. | $72.14 | 2024-2025 | Ycanth |
| Amgen INC. | $65.98 | 2023-2025 | Otezla, Otezla |
| Smith+Nephew, INC. | $45.39 | 2022-2023 | Grafix Pl |
| Merck Sharp & Dohme LLC | $44.86 | 2022-2023 | Keytruda |
| Epi Health, LLC | $41.06 | 2021-2022 | |
| Botanix Sb INC | $31.06 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $28.30 | 2023 | |
| Chiesi USA, INC. | $27.77 | 2023 | Cleviprex |
| Kyowa Kirin, INC. | $19.32 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Roche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.